This competing renewal application for the Delaware Valley (DV) Node requests 5 years of funding to continue its work. The DV Node, the Penn Center for Studies of Addiction of which it is a part, and the Treatment Research Institute where the Node is based, bring a wide range of expertise in selecting, conducting, and managing multi-site trials in community treatment programs. These qualities are reflected by our participation in 5 trials during the last period of funding including a study of extended buprenorphine- naloxone treatment for opioid addicted youth (#0010) that was developed and led by our Node, published in JAMA along with a commentary, and received national and international attention;a cost-effectiveness study that was developed by collaboration between Dr. Dan Polsky, a health services researcher at Penn and the DV Node, funded as an R01, and documented the costs and benefits of the two treatments in study #0010;a study of a computerized system to obtain patient feedback for therapists and program administrators that was developed and led by DV and resulted in additional NIDA grants to further explore its potential;a pharmacogenetic study of response to methadone and buprenorphine treatment that was led by a DV investigator;studies of HIV risk reduction in males and females;a study of OROS-MPH for substance abusing adolescents with ADHD;participating in CTN committees;helping develop protocols for new CTN studies;collaborating on papers from studies led by investigators at other Nodes;helping guide the career development of other investigators;giving keynote addresses at CTN Steering Committee and Blending meetings;having a Co-I selected as Deputy Drug Czar for Demand Reduction;and training fellows to conduct studies at international sites where data can be obtained that applies to the US but would be inordinately expensive or very difficult to do here and that extends the impact of the CTN beyond US borders. This work is done in collaboration with a wide range of investigators and sites that bring many different skills and patient populations to the CTN, and in the context of an infrastructure that can disseminate CTN findings to investigators, administrators and clinicians working in community based programs.

Public Health Relevance

This application will support an infrastructure to conduct clinical trials for persons with substance use disorders at community treatment programs in Philadelphia and other parts of the country. Its overall purpose is to conduct rigorous trials of promising treatment strategies in real world situations and disseminate the results with the overall goal of improving the quality of addiction treatment both nationally and internationally.

Agency
National Institute of Health (NIH)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10DA013043-15
Application #
8725102
Study Section
Special Emphasis Panel (ZDA1)
Program Officer
Dobbins, Ronald
Project Start
Project End
Budget Start
Budget End
Support Year
15
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Psychiatry
Type
Schools of Medicine
DUNS #
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Woody, George E; Bruce, Douglas; Korthuis, P Todd et al. (2014) HIV risk reduction with buprenorphine-naloxone or methadone: findings from a randomized trial. J Acquir Immune Defic Syndr 66:288-93
Winhusen, Theresa M; Kropp, Frankie; Lindblad, Robert et al. (2014) Multisite, randomized, double-blind, placebo-controlled pilot clinical trial to evaluate the efficacy of buspirone as a relapse-prevention treatment for cocaine dependence. J Clin Psychiatry 75:757-64
Doyle, Glenn A; Chou, Andrew D; Saung, Wint Thu et al. (2014) Identification of CHRNA5 rare variants in African-American heavy smokers. Psychiatr Genet 24:102-9
Mannelli, Paolo; Wu, Li-Tzy; Peindl, Kathleen S et al. (2014) Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open label trial. Drug Alcohol Depend 138:83-8
Dvoriak, Sergii; Karachevsky, Andrey; Chhatre, Sumedha et al. (2014) Methadone maintenance for HIV positive and HIV negative patients in Kyiv: acceptability and treatment response. Drug Alcohol Depend 137:62-7
Pecoraro, Anna; Ewen, Edward; Horton, Terry et al. (2014) Using the AUDIT-PC to predict alcohol withdrawal in hospitalized patients. J Gen Intern Med 29:34-40
Crits-Christoph, Paul; Gallop, Robert; Sadicario, Jaclyn S et al. (2014) Predictors and moderators of outcomes of HIV/STD sex risk reduction interventions in substance abuse treatment programs: a pooled analysis of two randomized controlled trials. Subst Abuse Treat Prev Policy 9:3
Pecoraro, Anna; Mimiaga, Matthew J; O'Cleirigh, Conall et al. (2014) Lost-to-care and engaged-in-care HIV patients in Leningrad Oblast, Russian Federation: barriers and facilitators to medical visit retention. AIDS Care 26:1249-57
Clarke, T-K; Crist, R C; Ang, A et al. (2014) Genetic variation in OPRD1 and the response to treatment for opioid dependence with buprenorphine in European-American females. Pharmacogenomics J 14:303-8
Otiashvili, David; Piralishvili, Gvantsa; Sikharulidze, Zura et al. (2013) Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior--outcomes of a randomized trial. Drug Alcohol Depend 133:376-82

Showing the most recent 10 out of 77 publications